Financial Data and Key Metrics Changes - Revenue for 2025 was $183.6 million, a 13% increase compared to 2024, exceeding the high end of guidance [20][21] - Adjusted EBITDA increased by 20% year-over-year to $26.7 million, with an adjusted EBITDA margin of 14.5% [23][20] - Free cash flow after distributions to non-controlling interest totaled $19 million, representing over 70% conversion from adjusted EBITDA [31][12] Business Line Data and Key Metrics Changes - Revenue growth was driven by a 69% increase in the U.S., while Canada saw a 7% decline and international revenue increased by 5% [16][20] - The acquisition of ResMetrics contributed $5.2 million to revenue for the year, enhancing the company's position in the tracer diagnostic space [20][5] - Adjusted gross profit for Q4 was $21.2 million, with an adjusted gross margin of 42%, slightly down from 43% in Q4 2024 [17][21] Market Data and Key Metrics Changes - The U.S. market showed strong performance, while Canada faced headwinds due to lower activity levels [16][20] - The company expects flat to lower overall customer activity in North America for 2026, with potential increases in international markets, particularly in the Middle East [26][27] Company Strategy and Development Direction - The company aims to advance efficient and sustainable energy development, targeting the $10 billion global completions market [6][4] - Core strategies include building market positions, capitalizing on high-margin growth opportunities, and commercializing innovative solutions [8][10] - The integration of ResMetrics is expected to enhance the company's tracer diagnostics platform and expand market reach [13][12] Management's Comments on Operating Environment and Future Outlook - Management anticipates a challenging market environment in 2026, with expectations of revenue growth primarily from U.S. and international markets [26][27] - The company aims to grow revenue in excess of underlying market activity and convert over 50% of adjusted EBITDA to free cash flow [14][29] - Management expressed confidence in the company's ability to utilize deferred tax assets, contributing to improved net income [19][23] Other Important Information - The company maintains a strong balance sheet with a net cash position of approximately $29 million and total liquidity of over $61 million [23][31] - Guidance for Q1 2026 includes expected revenue of $49 million to $53 million, with adjusted gross margin anticipated between 39% and 41% [24][25] Q&A Session Questions and Answers Question: Guidance on revenue weighting towards the back half of the year - Management indicated that seasonality affects revenue, with the majority of earnings and cash flow expected in the second half of the year [37][38] Question: Cross-selling potential in the Middle East with ResMetrics - Management noted that while benefits are seen in North America, international cross-selling will take more time to develop [40][42] Question: Updates on the North Sea pipeline and project opportunities - Management highlighted success in the North Sea, with new customer orders and ongoing projects, indicating a strong product-market fit [46][48]

Financial Data and Key Metrics Changes - For the full year of 2025, revenue was approximately $237,000, an increase from $96,000 in 2024 [6] - Net loss was approximately $20.3 million or a loss of $0.16 per share, an improvement from $22.5 million or a loss of $0.19 per share in 2024 [7] - R&D investment was approximately $11.5 million compared to $16.8 million in the prior year [7] - G&A expense was approximately $9.5 million compared to $6.4 million in the prior year [7] - Year-end cash position was approximately $69 million, roughly double the $34.9 million at the end of the third quarter [7] Business Line Data and Key Metrics Changes - Customer programs deepened in 2025, with three programs advanced to stage 3, prototype to final product [6] - Approximately 15 additional engagements are progressing through stage 1 and stage 2 [6] - The focus is on building durable, repeatable revenue streams supported by qualification and design wins [10] Market Data and Key Metrics Changes - The market for Ethernet optical transceivers of 100G and above and CPO reached approximately $16.5 billion in revenue in 2025, projected to reach approximately $26 billion in 2026, corresponding to a 60% growth rate [15] - AI clusters are expected to consume roughly 80% of Ethernet transceivers and CPO through 2031 [15] - 1.6 terabit per second transceivers revenue are expected to reach $1 billion in 2026 [15] Company Strategy and Development Direction - The strategy is to enhance silicon photonics rather than compete against it, allowing for higher bandwidth with lower power per bit [12] - The focus for 2026 includes advancing stage 3 programs towards qualification milestones, converting technical engagements into structured commercial agreements, and broadening the electro-optic polymer-ready silicon foundry ecosystem [17] - The company is preparing for scalable integration and not boutique deployment, with a disciplined approach to operational readiness [14] Management's Comments on Operating Environment and Future Outlook - The company remains confident in the AI opportunity and is committed to building long-term shareholder value [18] - The operational discipline is emphasized as critical for creating durable companies, with a focus on effective internal controls and IP protection [17] - The timeline for volume production and licensing revenues is not anticipated until 2027 at the earliest, reflecting the rigorous qualification cycles in the industry [10] Other Important Information - The company completed a public offering in December 2025, raising approximately $32.8 million in net proceeds [7] - The company is managing capital deliberately, with every dollar allocated towards commercialization readiness [8] - Device characterization and performance validation are expected in mid-2026 [13] Q&A Session Summary Question: What specific milestones remain to complete the technology transfer? - The company intends to proceed with back-end of line process and capacity expansion in Denver to support prototyping and final product qualification [20] Question: Can you provide guidance on production volume requirements for 2026? - The company is planning for success with aggressive assumptions related to production capacity and technician requirements [21] Question: Can shareholders expect to see an EOP modulator-based pluggable transceiver prototype completed this year? - The company will continue to update on progress towards stage four throughout 2026, but does not control the full transceiver program [22] Question: How will shareholders be updated regarding product progression with tier one partners? - The company will provide visibility through quarterly financial and business update calls [23] Question: What specific performance metrics will be validated for the mid-2026 device characterization? - The tapeout is a significant milestone to validate key design and performance parameters for modulators [24]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $1.9 million, a decrease from $5.8 million in Q4 2024, primarily due to lower development services revenue linked to a U.S. government shutdown [9][10] - Gross profit for Q4 2025 was $0.3 million (14.9% of revenue), compared to $0.9 million (15.5% in Q4 2024) [9][10] - Full year 2025 revenue was $17 million, down from $20.2 million in 2024, attributed mainly to the U.S. government shutdown and lower product sales [10][11] - Net loss for 2025 was $23.9 million ($2.10 per share), an improvement from a net loss of $30.2 million ($3.03 per share) in 2024 [12] Business Line Data and Key Metrics Changes - R&D expenses for Q4 2025 were $4.5 million, up from $3 million in Q4 2024, reflecting ongoing investment in the EscharEx VALUE phase 3 study [10] - SG&A expenses for Q4 2025 totaled $3.6 million, down from $4 million in the same period last year, mainly due to lower marketing and share-based compensation expenses [10] - The expanded manufacturing facility for NexoBrid is now operational, increasing production capacity sixfold to meet growing global demand [6][8] Market Data and Key Metrics Changes - Enrollment in the global phase 3 VALUE study for EscharEx is ongoing, targeting 216 patients across approximately 40 sites in the U.S. and Europe, with completion expected by year-end 2026 [5][6] - NexoBrid is being utilized across more than 70 burn centers in the U.S., representing the majority of Vericel's target accounts [6][8] Company Strategy and Development Direction - The company aims to advance EscharEx towards pivotal milestones and secure regulatory approvals for the expanded manufacturing facility, focusing on long-term value creation [15] - MediWound is expanding the EscharEx clinical program to include diabetic foot ulcers and pressure ulcers, aligning with both the FDA and EMA [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating ongoing geopolitical challenges and emphasized a focus on clinical milestones and commercial objectives [4] - The company reaffirmed its revenue guidance of $24 million-$26 million for 2026, with expectations of continued support from BARDA and the U.S. Department of Defense [14][15] Other Important Information - The company completed a $30 million registered direct offering and $3.5 million from Series A warrant exercises, strengthening its balance sheet [12][13] - The company plans to prioritize support for national preparedness initiatives, including stockpiling and collaboration with military and emergency response systems [8] Q&A Session Summary Question: Can you review the timing of MediWound filling demand for NexoBrid over the next 12-24 months? - The expanded manufacturing facility is operational, with a sixfold increase in capacity, and regulatory approvals are expected in late 2026, which will allow for market release [18] Question: Can you discuss the pressure ulcer trial and its potential market size? - The pressure ulcer indication is expected to be significant, potentially representing a third of the business, but further market research is needed to quantify the opportunity [26][27] Question: How much of the 2026 revenue guidance is based on new contracts versus existing awards? - The revenue guidance includes potential contributions from BARDA and the U.S. Department of Defense, but specific splits were not disclosed [30][33] Question: What is the status of the head-to-head study? - The head-to-head study is planned to start around mid-2026, which will help determine the pricing of EscharEx [70][71] Question: Will the interim analysis for the VALUE study be completed by year-end? - The interim analysis is expected to be completed by year-end, with no specific enrollment numbers shared to protect study integrity [72][77]

Liquidia (NasdaqCM:LQDA) Q4 2025 Earnings call March 05, 2026 08:30 AM ET Speaker7Good morning, and welcome to the Liquidia Corporation Full Year 2025 Financial Results and Corporate Update Conference Call. My name is Josh and I will be your operator today. All participants are currently in listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions for joining the queue will be provided at that time. Please note that today's call is being recorded. I'll now tur ...

Financial Data and Key Metrics Changes - For Q4 2025, consolidated revenue was $140 million, down 6.9% year-over-year, while full-year revenue was $561.1 million, compared to $572.5 million in 2024 [19][20] - Adjusted EBITDA for Q4 was $9.2 million, representing a 6.6% margin, compared to $14.5 million and 9.6% margin in the same period last year [25] - GAAP net loss for Q4 was $18.9 million or $0.22 per diluted share, an improvement from a net loss of $41.9 million or $0.59 per diluted share in the same period last year [24] Business Line Data and Key Metrics Changes - Product revenue in Q4 2025 fell to $97.6 million from $105.1 million in the same period last year, with system revenue at $37.8 million, up 18% sequentially [19] - Consumables revenue increased by 2.4% year-over-year to $69.8 million in Q4, while service revenue decreased to $42.4 million from $45.3 million [19][20] - For the full year, product revenue was $380.3 million, down from $392 million in 2024, and service revenue was $170.8 million, down from $180.5 million [20] Market Data and Key Metrics Changes - The aerospace and defense sector remains the largest vertical for the company, contributing significantly to revenue growth, particularly through partnerships with major players like Airbus and Boeing [9][10] - The automotive sector showed strong momentum, with significant wins from manufacturers like Subaru and Rivian, indicating a growing adoption of additive manufacturing technologies [11][12] Company Strategy and Development Direction - The company is focused on additive manufacturing, aiming to capture growth in high-value sectors such as aerospace, defense, automotive, and medical applications [6][7] - Strategic partnerships, such as those with nTopology and PostProcess Technologies, are aimed at enhancing workflow solutions and expanding market reach [13][15] - The company plans to maintain operational discipline while investing in technology leadership and exploring inorganic growth opportunities [31][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategic positioning and operational resilience, anticipating a return to growth in 2026 with revenue guidance of $565 million to $575 million [28][30] - The company expects to see improved profitability as market conditions normalize and capital spending constraints ease [8][31] - Management highlighted the importance of customer relationships and the company's established credibility in high-requirement sectors as key competitive advantages [36][62] Other Important Information - The company ended 2025 with a strong balance sheet, holding $244.5 million in cash and equivalents with no debt, providing stability for future growth [8][27] - Non-GAAP operating income for the full year was $8.3 million, compared to $4.9 million in 2024, indicating improved operational efficiency [26] Q&A Session Summary Question: Market size and growth outlook for aerospace and defense - Management emphasized their strong position in aerospace and defense, highlighting existing customer relationships and the expected growth in defense budgets [35][36] Question: Impact of FX and tariffs on guidance - Management clarified that the guidance includes current FX levels and potential adverse impacts from tariffs, with a focus on separating these from core business fundamentals [40][41] Question: Demand trends and seasonality in Q1 - Management noted that Q1 is typically the weakest quarter, but they expect sequential growth throughout the year, driven by new product launches and improving government and defense demand [48][49] Question: Material pricing and its impact on adoption - Management acknowledged that material pricing is a variable but emphasized their focus on high-value applications where price is less of a concern due to the unique requirements of the parts [56][62] Question: Update on large tech company's follow-up orders - Management stated they cannot disclose specific follow-up orders due to confidentiality but confirmed customer satisfaction with the solutions provided [67][69] Question: Revenue opportunity from SaaS qualifications - Management indicated that the qualification process for SaaS programs presents a large revenue opportunity, with timelines varying based on the class of parts being qualified [70]

Financial Data and Key Metrics Changes - Total sales increased by 11% in Q4 2025, following a 10% growth in Q4 2024, indicating strong market share gains [4][18] - Comparable store sales rose by 4%, building on a 6% increase from the previous year, resulting in a 10% two-year comp stack [5][26] - For the full year 2025, total sales grew by 9% on top of 11% growth in 2024, with comp sales increasing by 2% following a 4% increase in 2024 [8][21] - Operating margin expanded by 80 basis points for the full year, with a 22% increase in earnings per share compared to a 34% increase in the previous year [8][26] Business Line Data and Key Metrics Changes - The elevation strategy has led to higher comp growth rates in premium price segments, indicating successful execution in offering better brands and higher quality products [6][71] - Despite strong overall performance, certain categories such as home goods and gifting were underrepresented due to strategic adjustments in response to tariffs, which limited potential sales growth [12][33] Market Data and Key Metrics Changes - The company anticipates a favorable tax refund season, which is expected to positively impact sales, particularly in Q1 2026 [14][50] - The overall buying environment for off-price merchandise is described as excellent, with ample supply across most categories, supporting sales growth [55] Company Strategy and Development Direction - The company is optimistic about its sales outlook for 2026, raising comp guidance to 1%-3% due to favorable external and internal factors [16][39] - Continued focus on the Burlington 2.0 initiatives, including store experience improvements and merchandising localization, is expected to drive future growth [16][74] - The company plans to open approximately 110 net new stores in 2026, alongside a strategy of relocating and downsizing existing stores to improve performance and reduce occupancy costs [23][84] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of customers and the potential for increased sales driven by tax refunds and improved market conditions [14][50] - The impact of tariffs is expected to be less severe in 2026, as the industry has adjusted, allowing for more aggressive sales strategies without sacrificing margins [15][40] Other Important Information - The company ended Q4 with approximately $2.2 billion in total liquidity, including $1.2 billion in cash, and has no outstanding borrowings [20] - Inventory levels were strategically increased by 12% to prepare for anticipated higher traffic and sales in Q1 2026 [19][52] Q&A Session Summary Question: What drove your ahead of planned sales in Q4? - Management noted that while Q4 comp growth was strong, certain categories like home goods could have performed better if not for tariff-related adjustments [31][33] Question: How should we interpret the 1%-3% comp guidance for 2026? - The guidance reflects a more optimistic outlook based on recent performance and external factors, allowing for more aggressive planning [37][39] Question: Will higher tax refunds impact sales similarly to stimulus checks in 2021? - Management indicated that while higher tax refunds could boost sales, the impact is expected to be less significant than the 2021 stimulus checks [50][51] Question: How are inventory levels and merchandise supply? - Management expressed confidence in inventory levels, noting a deliberate increase to support anticipated sales growth, with a strong supply of off-price merchandise available [52][55] Question: Can you elaborate on the elevation strategy and its impact? - The elevation strategy has successfully improved customer perception and sales in higher price segments without negatively impacting margins, showcasing effective merchandising [71][72]

Financial Data and Key Metrics Changes - Fourth quarter sales were essentially flat year-over-year at $204 million, but would have increased by 3% excluding the impact of exiting low-margin products [4][14] - Adjusted operating margins expanded by 230 basis points to 11%, with adjusted EPS improving by 63% year-over-year [5][14] - Full year 2025 net sales decreased by 1.3% to $825.7 million, with adjusted gross margin increasing by 30 basis points to 33.7% [16] Business Line Data and Key Metrics Changes - Material Handling net sales decreased by $0.4 million, but would have increased by 3.4% excluding the impact of idling rotational molding facilities [15] - Distribution net sales increased by 0.9%, with adjusted EBITDA margin improving by 160 basis points [15] - Adjusted EBITDA margin for Material Handling was 25.6%, expanding by 290 basis points due to focused transformation savings [15] Market Data and Key Metrics Changes - Growth in industrial and infrastructure markets was offset by lower consumer and vehicle demand [5][16] - The backlog for matting products in the infrastructure segment is at its largest in the history of the business, indicating strong growth potential [20] - The food and beverage end market is forecasted to be slightly down for the year, reflecting agricultural market conditions [21] Company Strategy and Development Direction - The company is focused on a transformation program aimed at improving profitability and operational efficiency, with a goal of delivering consistent and reliable results [6][10] - Strategic priorities for 2026 include focusing on core markets, instilling operational excellence, and maximizing profitable growth through disciplined capital allocation [11][12] - The decision to sell Myers Tire Supply is part of a strategy to streamline operations and focus on high-margin growth platforms [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to control costs and improve profitability despite a challenging demand environment [5][6] - The outlook for 2026 includes moderate growth in industrial markets, driven by recovery in manufacturing capital expenditures and military demand [19][20] - The company is monitoring geopolitical conditions and their potential impact on demand trends [18] Other Important Information - Free cash flow improved by 23% to $67.2 million, with a cash balance of $45.1 million at year-end [16][17] - The company returned $23 million to shareholders through dividends and share repurchases in 2025 [17] Q&A Session Summary Question: Broader end market sentiment and breakdown of industrial subcategories - Management noted that industrial production has been strong, with specific product lines like Akro-Mils tracking closely with PMI improvements [26][27] Question: Demand from defense products and military sales - The company is selling directly to the U.S. military and NATO, with expectations for growth driven by geopolitical factors [32][34] Question: Material handling margins and sustainability of performance - Management indicated that the strong performance in material handling is expected to continue, supported by ongoing transformation efforts [36][39]

Financial Data and Key Metrics Changes - Revenue in Q4 was approximately $352 million, reflecting an increase of 50% year-over-year on an as-reported basis, primarily due to the acquisition impact [15] - Ex-TAC gross profit in Q4 was $152 million, an increase of 122% year-over-year on an as-reported basis, but a decline of 19% on a pro forma basis [18] - Adjusted EBITDA in Q4 was $37 million, and adjusted free cash flow was approximately $3 million in the fourth quarter and $6 million for the year [21] Business Line Data and Key Metrics Changes - CTV revenue crossed the $100 million annual mark with growth hitting 55% in Q4, indicating strong performance in the living room segment [5] - Sales to enterprise customers saw a 300% jump compared to Q3, demonstrating significant growth potential [5] - Direct response advertisers are focused on ROAS, with a small but meaningful segment of arbitrage-based customers being turned away for higher quality [12] Market Data and Key Metrics Changes - The U.K. market has stabilized, and sales of performance campaigns to enterprise customers are accelerating [17] - The operational challenges primarily impacted the U.S. and U.K. markets, but improvements are being seen in Q1 [17][36] Company Strategy and Development Direction - The company aims to build a best-in-class digital advertising platform, focusing on premium marketplace growth and walking away from low-quality revenue [4] - The strategy for enterprise advertisers is built on three pillars: leading with CTV offerings, deepening relationships with agencies, and scaling performance business [7][11] - The company is investing in AI to enhance performance and productivity, aiming to simplify campaign setups and optimize outcomes [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to growth by Q4 2026, citing positive indicators from Q4 and early Q1 [14][36] - The company acknowledges the uncertainty of the overall environment but is focused on executing a well-defined plan to drive growth [22] Other Important Information - The company recorded a non-cash impairment to goodwill of around $350 million due to declines in share price and market capitalization, which does not impact liquidity or cash flows [19] - Restructuring is expected to save approximately $35 million-$40 million annually [20] Q&A Session Summary Question: Is the sales force fully staffed now, and what about exclusive deals with Samsung and LG? - Management is confident in the current leadership and team, and exclusive relationships exist with LG and Samsung in certain geographies, enhancing their competitive advantage [26][27] Question: Can you provide additional color on the stabilization of the business and trends in Q1? - Management sees improvement in Q1, particularly in CTV and performance sales, with a focus on reducing costs and realigning around growth drivers [32][36] Question: What are the assumptions behind the full year EBITDA guide? - The guidance of approximately $100 million of EBITDA does not imply full-year Ex-TAC growth, with expectations of returning to growth by Q4 [41][43] Question: Any specific ad verticals showing strength or weakness? - There is some weakness in CPG and automotive, while health and finance sectors show strength, but nothing material to report [46] Question: Can you elaborate on the Google TV opportunity? - The addition of Google TV is seen as a significant growth opportunity for CTV home screen, with expectations of continued strong growth [50]

Financial Data and Key Metrics Changes - The net loss attributable to common stockholders for Q4 2025 was $36.9 million, representing an 11% year-over-year improvement, while the full year net loss was $116.7 million, reflecting a 24% improvement [23] - Non-GAAP adjusted net loss for Q4 2025 was $17.5 million, a 9% improvement year-over-year, and for the full year, it was $54.1 million, showing a 49% improvement [23] - Total consolidated revenues for Q4 2025 were $29.5 million, a 7% year-over-year increase, while full year revenues were $130.4 million, essentially flat compared to the previous year [24] Business Line Data and Key Metrics Changes - Hospitality segment revenues declined by 23% in Q4 2025 on a pro forma basis, primarily due to lower performance at the Tin Building [25] - Entertainment segment revenues increased by 68% year-over-year in Q4 2025, driven by the internalization of Enchant operations in Las Vegas [29] - Landlord segment rental revenue increased by 14% year-over-year in Q4 2025, mainly from private events rental revenue [31] Market Data and Key Metrics Changes - The Seaport neighborhood was approximately 90% leased or programmed as of December 31, 2025, leaving roughly 47,000 sq ft of vacancy [17] - The company anticipates that leasing or programming more than 220,000 sq ft since becoming a standalone public company will result in additional stabilized EBITDA of over $30 million [17] Company Strategy and Development Direction - The company aims to position itself as a scalable, real estate-centric hospitality and entertainment company, focusing on improving operations and expanding offerings [3] - The sale of 250 Water Street is expected to eliminate $7 million of annual cash burn and provide additional capital for strategic priorities [6] - The company plans to expand the Pier 17 event space from 17,500 sq ft to over 40,000 sq ft, targeting large-scale meetings and events [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's progress and the potential for long-term financial stability, highlighting the positive momentum from 2025 into 2026 [20] - The company is focused on improving its cost structure and operational efficiency, with expectations for continued margin improvement in 2026 [19] Other Important Information - The company has a strong cash position of over $87 million, which would increase to $163 million pro forma after the sale of 250 Water Street, providing liquidity for future investments [41][42] - The company is exploring the sale of its 21-unit apartment building at 85 South Street, which is nearly fully leased and cash flowing [70] Q&A Session Summary Question: How much of the $163 million cash is committed to current projects? - The company expects to spend around $70 million-$90 million to stabilize existing projects, targeting a total of $100 million-$125 million for stabilization [45] Question: What are the criteria for the buyback program? - The buyback program will be executed opportunistically, with no specific parameters or timing publicly disclosed [62][64] Question: How does the Balloon Museum complement the Meow Wolf experience? - Both experiences are seen as complementary, providing a full day opportunity for visitors at the Seaport [67] Question: What is the status of the apartment building at 85 South Street? - The building is nearly 100% leased and cash flowing, with significant interest in the marketing process [68] Question: How do the Las Vegas properties fit into the company's overall strategy? - The Las Vegas ballpark is positioned well within a growing community, and the company sees opportunities to enhance profitability through better cost controls and creative ticketing strategies [72]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $5.5 million, and for the full year 2025, revenues were $49.8 million, compared to $25 million in upfront payment from Viatris in 2024 [24][26] - Research and development expenses decreased to $11.3 million in Q4 2025 from $26.7 million in 2024, and full year R&D expenses decreased to $61.1 million from $84.5 million [25] - Selling, general and administrative expenses for Q4 2025 decreased to $8.8 million from $32.3 million in 2024, and full year SG&A expenses decreased to $37.3 million from $143.1 million [25] - Net loss for Q4 2025 was $15.5 million or $0.04 per share, compared to a net loss of $33.8 million or $0.09 per share in Q4 2024 [26] - As of December 31, 2025, cash investments and restricted cash totaled $125.2 million, down from $238 million at the end of 2024 [27] Business Line Data and Key Metrics Changes - The company is advancing three late-stage programs: sotagliflozin for cardiometabolic disease, pilavapadin for chronic pain, and LX9851 for obesity [4][5] - Sotagliflozin is in late-stage development for hypertrophic cardiomyopathy (HCM) and type 1 diabetes, with an NDA resubmission expected in 2026 [6][18] - Pilavapadin is phase 3-ready for diabetic peripheral neuropathic pain (DPNP), with a successful end of Phase 2 meeting with the FDA [20][22] Market Data and Key Metrics Changes - The company is focusing on the cardiometabolic disease and chronic pain markets, with significant unmet needs in both areas [10][12] - There are approximately 1 million patients with type 1 diabetes in the U.S., with no new therapies approved for over a century [18] - The SONATA-HCM Phase 3 study is the only registrational trial currently enrolling patients with both obstructive and non-obstructive HCM [14][15] Company Strategy and Development Direction - The company aims to maintain operational discipline and improve its financial position to support core programs [8] - A partnership strategy is in place to support existing licensees and explore new partnerships, particularly for pilavapadin [7] - The company is focused on driving multiple pivotal milestones in 2026 across its core programs [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming milestones and the potential for substantial value creation from its pipeline [30][31] - The company is excited about the progress made in 2025 and the potential opportunities in 2026, emphasizing the importance of addressing unmet medical needs [30][31] Other Important Information - The company has strengthened its cash position with over $100 million from a recent capital raise and a milestone payment from Novo Nordisk [8][27] - The company plans to reduce total operating expenses to between $100 million and $110 million in 2026 [29] Q&A Session Summary Question: What is the status of the Steno-1 study data for DKA safety? - Management expects a 6-month review for the NDA resubmission and is confident in the data supporting submission and approval timelines [33][36] Question: How have the Phase 2 results accelerated partnering discussions for pilavapadin? - Discussions with partners have become more specific following the end of Phase 2 meeting, but no acceleration in discussions has been noted [38][39] Question: What are Novo Nordisk's plans for LX9851? - The company believes Novo is exploring various options for LX9851, including its use in combination therapies for obesity management [40][41] Question: Is there flexibility to start the pilavapadin study without a partner? - The company is focused on cardiometabolic opportunities and is preparing for the Phase 3 program while engaging in partnership discussions [46][48] Question: How confident is the company in achieving the enrollment target for SONATA-HCM? - Management is confident in meeting the mid-year enrollment target, with strong enrollment trends observed across all regions [60][64] Question: What changes will be made to the Phase 3 design of the pilavapadin program? - The company plans to expand enrollment criteria and enhance patient training on pain score assessments to improve consistency [67][70]